UNIGE document Scientific Article
previous document  unige:156586  next document
add to browser collection
Title

Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls

Authors
Remy, Amandine
Théorêt, Yves
Bittencourt, Henrique
Ducruet, Thierry
Pastore, Yves
Rezgui, Mohamed A
show hidden authors show all authors [1 - 10]
Published in Journal of pediatric hematology/oncology. 2021, vol. 43, no. 6, p. e867-e872
Abstract In busulfan-based conditioning regimen for hematopoietic stem cell transplantation in children, accurate a priori determination of the first dose is important because of its narrow therapeutic window. Sickle cell disease (SCD) influences pharmacokinetics of the commonly used drugs by affecting organs responsible for drug metabolism and elimination. This pharmacokinetics study assesses the influence of SCD on the metabolic pathway of busulfan that is mainly metabolized in the liver. In this retrospective cross-sectional case-control study, 16 patients with SCD were matched to 50 patients without SCD on known busulfan clearance's covariates (glutathione-S-transferase alpha1 polymorphisms, age, weight). Clearance of the first dose of busulfan was not significantly different independently of genetic or anthropometric factors in patients with or without SCD.
Keywords AdolescentAdultAnemia, Sickle Cell / metabolismAnemia, Sickle Cell / therapyBusulfan / metabolismBusulfan / pharmacokineticsCase-Control StudiesChildChild, PreschoolCross-Sectional StudiesFemaleHematopoietic Stem Cell TransplantationHumansImmunosuppressive Agents / metabolismImmunosuppressive Agents / pharmacokineticsMaleMetabolic Networks and PathwaysRetrospective StudiesTransplantation ConditioningYoung Adult
Identifiers
PMID: 33661168
Full text
Structures
Research group Oncologie et hématologie pédiatriques (907)
Citation
(ISO format)
REMY, Amandine et al. Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls. In: Journal of pediatric hematology/oncology, 2021, vol. 43, n° 6, p. e867-e872. doi: 10.1097/MPH.0000000000002106 https://archive-ouverte.unige.ch/unige:156586

16 hits

0 download

Update

Deposited on : 2021-11-22

Export document
Format :
Citation style :